This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Clarcor, Transcept: After-Hours Trading

Transcept Pharmaceuticals

A big mover to the upside late Wednesday was Transcept Pharmaceuticals (TSPT), whose stock soared after the company announced a plan to resubmit the new drug application for its proposed insomnia drug Intermezzo by the end of the month.

The shares jumped 13.8% to $3.80 on extended-session volume of almost 280,000.

Transcept is seeking approval for the tablet "for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep." The plan to resubmit the application follows the company meeting with the FDA and reaching a general agreement with the regulator to reduce the recommended dosage for women to 1.75 milligrams from 3.5 milligrams, while leaving the 3.5 milligram dosage in place for men.

The company added that, based on its discussions with the FDA, it doesn't expect to conduct additional clinical studies of Intermezzo prior to resubmitting the new drug application. It also proposes to include additional instructions on safe usage of the drug.

Another stock in action after the close included Ascena Retail Group (ASNA - Get Report), whose stock lost 8% to $25.96 on volume of more than 30,000 after the Suffern, N.Y.-based company's fiscal fourth-quarter earnings came in a penny short of analyst expectations.

-- Written by Michael Baron in New York.
Disclosure: TheStreet's editorial policy prohibits staff editors, reporters and analysts from holding positions in any individual stocks.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ASNA $9.04 2.61%
CLC $59.04 0.46%
TSPT $30.00 0.67%
AAPL $93.64 -0.11%
FB $118.57 0.84%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs